Table 3.
Prognostic factors associated with PFS and OS after PSM.
| Variables | Progression-free survival | Overall survival | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age (years) ≤60/>60 |
1.559 | 0.768-3.166 | 0.219 | 1.866 | 0.798-4.364 | 0.150 | ||||||
| Sex Female/Male |
0.686 | 0.339-1.388 | 0.295 | 0.911 | 0.401-2.070 | 0.823 | ||||||
| ECOG PS 0/1+2 |
1.149 | 0.549-2.404 | 0.712 | 1.862 | 0.725-4.785 | 0.196 | ||||||
| Child-Pugh class A5/A6+B7 |
0.809 | 0.468-2.645 | 0.809 | 2.021 | 0.775-5.273 | 0.150 | ||||||
| CA199 (u/ml) ≤37/>37 |
0.665 | 0.298-1.485 | 0.320 | 1.256 | 0.464-3.399 | 0.653 | ||||||
| CEA (ug/ml) ≤5/>5 |
1.202 | 0.566-2.556 | 0.632 | 1.495 | 0.582-3.840 | 0.404 | ||||||
| AST (U/L) ≤40/>40 |
1.003 | 0.458-2.196 | 0.994 | 1.145 | 0.484-2.709 | 0.759 | ||||||
| ALT (U/L) ≤35/>35 |
0.775 | 0.372-1.614 | 0.775 | 1.638 | 0.641-4.188 | 0.303 | ||||||
| Albumin level (g/L) ≤35/>35 |
0.337 | 0.188-1.770 | 0.337 | 0.278 | 0.110-1.112 | 0.216 | ||||||
| Tumor number Single/Multiple |
1.379 | 0.678-1.805 | 0.035 | 1.721 | 0.452-3.120 | 0.045 | 1.204 | 0.525-1.762 | 0.061 | 1.452 | 0.567-2.148 | 0.032 |
| Tumor size (cm) ≤5/>5 |
2.436 | 1.060-5.600 | 0.036 | 2.749 | 1.185-6.378 | 0.019 | 2.117 | 0.922-4.863 | 0.067 | 1.961 | 1.124-3.321 | 0.023 |
| Tumor differentiation II/III+IV |
1.189 | 0.531-2.662 | 0.674 | 1.623 | 0.551-4.781 | 0.379 | ||||||
| Extrahepatic metastasis Yes/No |
0.841 | 0.376-1.883 | 0.674 | 0.616 | 0.209-1.814 | 0.379 | ||||||
| Treatment DEB-TACE+ICIs/Chemotherapy |
2.170 | 1.020-4.619 | 0.044 | 2.481 | 1.150-5.354 | 0.021 | 2.906 | 1.174-7.194 | 0.006 | 2.882 | 1.153-7.203 | 0.024 |
Analyses were performed using Cox’s proportional hazards regression model. PFS, progression-free survival; OS, overall survival; PSM, propensity score matching; HR, Hazard Ratio; CI, confidence interval; ECOG PS, ALT, alanine transaminase; Eastern Cooperative Oncology Group performance score; TBIL, total bilirubin; AST, aspartate transaminase; DEB-TACE+ICIs, drug-eluting bead transarterial chemoembolization combined with immune checkpoint inhibitor.